12:00 AM
Nov 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

5G1: Phase I data; Phase II

ALXN reported additional data from its 42-patient single-dose Phase I study, showing that 3 of 6 patients receiving the highest dose of the antibody...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >